Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
JBCHEPHARM
Suresh Amin · Mumbai, India · 5,602 employees
₹2,416.10
▲+0.30%JBCHEPHARM's strong analyst consensus and robust institutional backing are not yet matched by improving performance, with revenue growth still lagging behind peers.
Exchange
NSI
Currency
INR
Day range
₹2,380.00 – ₹2,525.50
52-week range
₹1,638.50 – ₹2,525.50
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis60% confidence
Trading near the upper third of its 1-year range at 54.22 times P/E, despite a relatively stable and well-performing business, may leave some room for valuation normalization.
4.3% below the 1-year high · trend up
Hedge-fund memo
Today
JBCHEPHARM rose 0.30% today, supported by a solid analyst consensus and robust institutional ownership, though the stock's near-term momentum is influenced by revenue growth contraction.
This week
Price fluctuates between Rs. 2380 and Rs. 2525.5 on moderate volume.
This month
JBCHEPHARM's share price has maintained a relatively stable trajectory since mid-2023.
Bull thesis
Bear thesis
News & sentiment
Bullish
1 headlines · 1 outlets · 7d
TradingView·4d ago·large multi-year AI deal
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 4 recent quarters (EPS actual vs. consensus).
7.5954 vs 8.4
-9.58% surprise
12.45 vs 12.5
-0.40% surprise
13.08 vs 12.9
1.40% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| JBCHEPHARM | 387.93B | 54.22 | 18.69% | 16.48% | -4.80% |
| IPCALAB | 450.20B | 39.52 | 13.22% | 18.48% | 6.30% |
| AJANTPHARM | 424.34B | 40.17 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 496sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Generic competition and patent expirations
Mitigation: Investment in R&D to maintain product pipeline
Regulatory issues with existing products
Mitigation: Diversification of product portfolio
Business intelligence
Competitive moat
JBCHEPHARM's strong brand reputation, established product pipeline, and efficient operations form a durable competitive advantage.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Expansion into emerging markets
Thesis builder
Bull case
Revenue growth stabilization and entry into emerging markets, driven by strategic partnerships
Base case
Expansion into high growth regions, coupled with efficient cost management
Bear case
Intensifying generic competition and potential regulatory issues, leading to stagnant share price
Time horizon
1-3 years
Est. CAGR
approx 10-15%
Entry (qual.)
Invest when signs of improving revenue growth emerge, supported by stable institutional backing
Exit (qual.)
Consider divestment when generic competition accelerates or regulatory concerns escalate
Overall conviction 60%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how JBCHEPHARM fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain JBCHEPHARM for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Investors should maintain a position and focus on long-term prospects, considering strategic partnerships and emerging market expansion
Annual income statement, oldest → newest. Live via Yahoo.
12.75 vs 13.6
-6.25% surprise
| 25.39% |
| 23.19% |
| 21.50% |
| APLLTD | 159.60B | 23.67 | 12.36% | 7.39% | 4.40% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹2,380.00
Resistance (day/52w high)
₹2,525.50
Volume
47,79,224
Trend
up
RSI (14)
59
MACD
bearish
MA cross
golden
50-day MA
₹2,271.08
200-day MA
₹2,003.10
vs 200-DMA
20.6%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.